Disintegrin variants and pharmaceutical uses thereof,申请号AU20070343734-传众专利搜索

Disintegrin variants and pharmaceutical uses thereof

申请公布号：AU2007343734(B2)

申请号：AU20070343734

申请日期：2007.12.21

申请公布日期：2014.01.30

申请人：

NATIONAL TAIWAN UNIVERSITY

发明人：CHUANG, WOEI-JER;HUANG, TUR-FU;CHEN, CHIU-YUEH;HUANG, WENYA;FU, WEN-MEI;TANG, CHIH-HSIN

分类号：C07K14/00;A01N37/18;A61K38/00;C07H21/04;C07K1/00;C07K17/00;C12N1/20;C12N15/74;C12P21/06

主分类号：C07K14/00

摘要：Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin avß3 receptor-antagonist activity and substantially reduced integrin aIIbß3 and/or a5ß1 receptor-blocking activity as compared to a wild-type disintegrin. The variant is encoded by a modified disintegrin nucleotide sequence that encodes a modified amino acid sequence, resulting in a polypeptide having substantially reduced affinity to integrin aIIbß3 and/or a5ß1 as compared to a wild-type disintegrin. The variant is useful for treatment and/or prevention of avß3 integrin-associated diseases in a mammal, which include osteoporosis, bone tumor or cancer growth, angiogenesis-related tumor growth and metastasis, tumor metastasis in bone, malignancy-induced hypercalcemia, angiogenesis-related eye diseases, Paget's disease, rheumatic arthritis, and osteoarthritis. The angiogenesis-related eye diseases include age-related macular degeneration, diabetic retinopathy, corneal neovascularizing diseases, ischaemia-induced neovascularizing retinopathy, high myopia, and retinopathy of prematurity.